Sun Pharmaceutical Industries Limited — PPTs, 26-12-2025: Investor Presentation

Sun Pharma reported H1 FY26 Gross Sales of **Rs 28,191.3 Cr**, up 9.3% YoY. Adjusted Net Profit for the half-year stood at **Rs 6,114.1 Cr**, a 4.1% YoY increase, with an Adjusted EPS of **Rs 25.5**. Q2 FY26 EBITDA margin was strong at 31.3%. India formulations grew 12.4% in H1, while Emerging Markets and Rest of World also saw robust growth. US formulations were relatively flat in Q2.

The company aims to enhance its innovative and complex product portfolio, targeting key therapy areas like Dermatology and Oncology. Strategic focus includes acquisitions to expand offerings, such as Checkpoint Therapeutics for anti-PD-L1 treatment and Concert Pharma for alopecia areata. Operational efficiency and vertical integration remain key priorities for cost optimization.

Sun Pharma plans for mid to high single-digit consolidated topline growth for FY26, emphasizing sustainable and profitable expansion and improving overall return ratios. The company continues to invest in R&D, building its innovative medicines pipeline and developing complex generic products.